We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis Hit With Subpoena From DOJ Over Marketing and Pricing of Heart Drug Entresto
Novartis Hit With Subpoena From DOJ Over Marketing and Pricing of Heart Drug Entresto
Novartis has received a request from the Department of Justice (DOJ) asking for information about the marketing and pricing of Entresto, the company’s blockbuster combination sacubitril/valsartan drug for heart failure.